SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Guided Therapeutics - GTHP
GTHP 0.2700.0%Oct 31 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BitWizrd who wrote (29)8/27/1998 1:41:00 PM
From: Robin  Read Replies (1) of 118
 
Mr. Wizard,

I don't get it! This is the exact approach (using proven test strip technology) that SPRX has been using all along. In this regard, this would place SPRX well ahead of NTEG!

Collecting the ISF is only part of the problem. NTEG states that they can reliably collect 1uL of ISF, while SPRX states they are taking steps to improve the amount of ISF collected. So NTEG may be slightly ahead of SPRX here, although public perception of the capability of either instrument to collect fluid could be affected more by company hype (press releases) from either company rather than actual field data. Personally, I find SPRX reserved and to the point in their press releases.
As for test strip technology, SPRX has been working closely with Abbott for some time now on perfecting strip technology for ISF. Who has NTEG been working with (or plans to work with) on this? It seem logical to me that SPRX is likely to be far ahead of NTEG in this area.
If anything, this announcement of abandoning IR will have a greater impact on BICO and Futrex than on SPRX and could quite likely put both finally out of business. If IR doesn't work, I don't see much impact on SPRX other than reducing the competition they face.

Rockin' Robin
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext